Abstract: The present invention discloses a catalytic hydrogenation method for carbon nine resin, comprising the following steps: 1) adding a Pt—W—Y/?-Al2O3 catalyst in the first half of a fixed bed, adding a Pd—Zr—Nd/?-Al2O3 catalyst in the second half of the fixed bed, and feeding hydrogen for reduction; and 2) catalytic hydrogenating the pretreated carbon nine resin in the fixed bed. In the present invention, different catalysts capable of reacting under the same catalytic conditions are added in the first and second halves of the fixed bed, and the two different catalysts play different roles, and can be active and complementary to each other under the same conditions. The synergistic effect of the two catalysts plays a good catalytic role. Moreover, the production process is simplified, and the production cost is saved.

Abstract: The present invention relates to the technical field of chemical drug synthesis, and specifically relates to a method for preparing a compound as shown in formula I, comprising: treating the compound as shown in formula VII with an acid to generate the compound as shown in formula I. The method has few synthetic process steps, raw materials which is stable and is easy to prepare, a reaction process which is easy to control, and a high overall yield and purity, and is suitable for industrial preparation.

Abstract: Disclosed is a method for preparing a C-nucleoside compound represented by Formula (III) or salt thereof. The present method has a high reaction yield, is simple to operate, uses a single metal reagent, has stable reaction temperature conditions, does not require frequent changes to the reaction system during the operation process, is suitable for scale-up synthesis, is suitable for large-scale production of Remdesivir, and has low costs.

Abstract: Crystalline forms and pharmaceutical composition of a PRMT5 inhibitor of formula (I), methods of making PRMT5 inhibitor of formula (I) and crystalline forms thereof, methods of making the pharmaceutical compositions of the PRMT5 inhibitor of formula (I) and methods of using the PRMT5 inhibitor of formula (I) or crystalline solid forms and pharmaceutically acceptable compositions thereof.

Abstract: The present application provides a medicament having an anti-inflammatory bowel disease function, and a preparation method therefor and an application thereof. The medicament has a structure as represented in formula I or formula II. The medicament and a pharmaceutically acceptable salt, a solvate, a prodrug, a tautomer, a stereoisomer, or a pharmaceutical composition thereof provided by the present application have a good effect on inflammatory bowel diseases, can be used for preparing medicaments for treating the inflammatory bowel diseases, and have important clinical significance and wide application prospects.

Abstract: The present application provides a medicament having an anti-inflammatory bowel disease function, and a preparation method therefor and an application thereof. The medicament has a structure as represented in formula I or formula II. The medicament and a pharmaceutically acceptable salt, a solvate, a prodrug, a tautomer, a stereoisomer, or a pharmaceutical composition thereof provided by the present application have a good effect on inflammatory bowel diseases, can be used for preparing medicaments for treating the inflammatory bowel diseases, and have important clinical significance and wide application prospects.

Abstract: Described are techniques for synchronizing system times. A request is sent from a first system to a second system to obtain a current remote system time. A first time value denotes a time when the request is sent. A response, including the current remote system time, is received from the second system. A second time value denotes a time when the response is received by the first system. An average of the first time value and the second time value is determined A difference between the current remote system time and the average is determined. It is determined whether the difference is more than an endurance value. Responsive to determining the difference is more than the endurance value, the difference is used to convert a remote system time of the second system to an equivalent local system time of the first system.

Abstract: Techniques are disclosed for monitoring the performance of transient virtual volumes created for a virtual machine. Each transient virtual volume is created in response to a first trigger event, used by the virtualization environment solely to perform a single function supporting execution of the virtual machine, and deleted in response to a second trigger event. When creation of a current transient virtual volume is detected, and while the virtualization environment uses the current transient virtual volume to perform a single function supporting execution of the virtual machine, performance data is collected for the current transient virtual volume, and combined with performance data collected for at least one other, previously deleted transient virtual volume that was used solely to perform the same single function supporting execution of the same virtual machine. The combined performance data is represented as performance data for a single monitored virtual volume associated with the virtual machine.

Abstract: Techniques for visualizing performance of file-based VVols and block-based VVols for aiding in administration of a data storage system operating in a virtualization environment allow performance of these different types of VVols to be visualized side-by-side using a common set of performance metrics. Thus, in one embodiment, the performances of file-based and block-based VVols are both converted into a mutually-compatible format and rendered for display together on screen.

Abstract: Techniques for visualizing performance of VVols for aiding in administration of a data storage system operating in a virtualization environment allow performance of these VVols to be visualized in a highly-flexible manner. Thus, in one embodiment, the performances of all VVols within a storage container are aggregated together for easy comparison among the aggregated performances of different storage containers.

Abstract: Provided herein are methods of accelerating bone fracture healing in a subject. Also provided herein are methods of treating or preventing osteoporosis in a subject. Further provided are methods of screening for an agent that accelerates bone fracture healing or treats or prevents osteoporosis.